MORGAN STANLEY PLC/CALL/ABBVIE/270/0.1/20.06.25 Share Price

Warrant

DE000ME9VM36

Real-time Bid/Ask 02:48:01 23/05/2024 pm IST
0.067 EUR / 0.102 EUR +7.59% Intraday chart for MORGAN STANLEY PLC/CALL/ABBVIE/270/0.1/20.06.25
Current month-12.22%
1 month-31.30%
Date Price Change
22/24/22 0.079 -1.25%
21/24/21 0.08 -2.44%
20/24/20 0.082 -2.38%
17/24/17 0.084 +1.20%
16/24/16 0.083 -1.19%

Delayed Quote Börse Stuttgart

Last update May 22, 2024 at 11:59 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
Issuer Morgan Stanley
WKN ME9VM3
ISINDE000ME9VM36
Date issued 08/03/2024
Strike 270 $
Maturity 20/06/2025 (394 Days)
Parity 10 : 1
Emission price 0.13
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.231
Lowest since issue 0.068
Delta0.05x
Omega 9.007
Premium69.74x
Gearing172.24x
Moneyness 0.5911
Difference Strike 110.4 $
Difference Strike %+40.89%
Spread 0.037
Spread %35.58%
Theoretical value 0.0855
Implied Volatility 27.98 %
Total Loss Probability 97.11 %
Intrinsic value 0.000000
Present value 0.0855
Break even 270.93 €
Theta-0x
Vega0.02x
Rho0.01x

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
159.6 USD
Average target price
182.3 USD
Spread / Average Target
+14.19%
Consensus